’Steno Partner agreements’ have now been concluded with three acute care hospitals (Bispebjerg and Frederiksberg Hospital, Amager and Hvidovre Hospital, and Nordsjællands Hospital) and with Rigshospitalet and Bornholm’s Hospital. A transitional agreement has been established with the final acute care hospital, Herlev Gentofte that will run until 2020, when SDCC moves to Herlev.
A ‘Steno Partner agreement’ means that both parts to the agreement want a binding collaboration on a number of supplementary treatment initiatives, clinical research, training and health promotion in relation to diabetes.
Niels Reichstein Larsen, Chief Executive at Bornholm’s Hospital is very pleased with the agreement:
“This is a good agreement and it’ll help us make sure that we’re all at the same level in the region. We’ll be able to become a more integrated part of a larger specialist community in which research and the quality of treatment are improved.”
The Assistant Director at Bispebjerg and Frederiksberg Hospital, Kurt Espersen, is also positive:
“This is the start of something good for the diabetes field as a whole, and for all the hospitals because we now have uniform focus on treatment, training and research.”
The first treatment initiatives are on the way
The handbook for SDCC describes a number of treatment initiatives within various areas of diabetes, such as chiropody, treatment kidney and heart complications. An inter-disciplinary working group will be set up for each initiative to describe how treatment for each area can be improved regionally. For example, the working group within chiropody is describing the standard for foot treatment in the region and how the standard can be improved further throughout the region in the years to come.
“At Bispebjerg and Frederiksberg Hospital, the knowledge centre for wounds and sores has focussed on treating sores for diabetes patients. Establishing a chiropody clinic at all acute care hospitals on the basis of the knowledge and competences from the centre will raise the quality in the region and help set the framework for the best treatment for all the diabetes patients in the region,” said Kurt Espersen.
The treatment initiatives are one of several examples of possible collaboration between SDCC and Steno Partners. Each Steno Partner receives DKK 1.25 mill. annually to recruit personnel, including a coordinator who is to ensure progress and implementation of the many initiatives.
Diabetes treatment to continue locally
Treatment of people with diabetes will continue more or less unchanged at hospitals in the region. Today, there are 105,000 people with type 1 or type 2 diabetes in the region, and they either go to a hospital for check-ups or to their GP. In addition to consolidating newly diagnosed type 1 diabetics, type 1 diabetics with pumps and children with diabetes at SDCC, in the future diabetics will also be treated in their own catchment area in the region.
“We think that the best part of the agreement is that we can maintain many of the local initiatives that we’ve implemented ourselves, such as our diabetes hotline and our good inter-sectoral collaboration in the diabetes field,” said Kurt Espersen.
“We work on the principle that the patient’s situation should direct the process. This means that we want as much treatment as possible to be available locally on Bornholm. Therefore, we have to find a cooperation model like a satellite function or telemedicine solutions so that people can be examined and treated on Bornholm,” said Niels Reichstein Larsen.
“During my three tours around the acute care hospitals and Rigshospitalet and Bornholm’s Hospital over the past four months, I’ve been impressed by the numerous good activities going on at the region’s hospitals, and it’s not hard to see the opportunities ahead in together learning from each other’s experience,” said the CEO at SDCC, Allan Flyvbjerg.
The agreements will be regularly evaluated over the next three years and then renegotiated with a view to extension on the basis of experience obtained during the first period.